

h Eotaxin h MCP-1 h ENA-74 h BCA-1 Figure 1B





Figure 1C






Figure 1E






Figure 1F








Figure 1H




Figure 1I




Figure 2





Figure 3 ¥ ¹²⁵l I-TAC (percent inhibition) ¹²⁵l I-TAC (percent inhibition) 100-CK Alone 75 CK + SDF-1β(~90nM) 75-CK + MIG (~175nM) 50 25 25-0-0 -12 -10 -11 -6 <u>-7</u> -9 -10 -11 -7 -8 -6 ml-TAC (logM) hI-TAC (logM) ¹²⁵l I-TAC (percent inhibition) ¹²⁵_l I-TAC (percent inhibition) ₮ 100-75-75 50-50 25 25 0 -11 -7 -10 -11 -12 -9 -10 -7 -9 -6 hMIG (logM) hIP-10 (logM) • SDF-1β Ī ¹²⁵_l I-TAC (percent inhibition) ¹²⁵l I-TAC (percent inhibition) O SDF-1β+ MIG(~175nM) 100-100-75-75 o MIG MIG + SDF-1 β (~90nM) 50 50-25-25 0 0 -12 -11 -11 -10 -7 -9 -10 -6 . 8--6 hMIG (logM) hSDF-1β (logM)

Figure 4
MDA MB 435s CXCR7



MDA MB 435s wt




Figure 5




Figure 6




Figure 7




Figure 8

Mean tumor volumes

